WO1997033633A1 - Adhesif pour tissus, applique par pulverisation - Google Patents
Adhesif pour tissus, applique par pulverisation Download PDFInfo
- Publication number
- WO1997033633A1 WO1997033633A1 PCT/JP1997/000818 JP9700818W WO9733633A1 WO 1997033633 A1 WO1997033633 A1 WO 1997033633A1 JP 9700818 W JP9700818 W JP 9700818W WO 9733633 A1 WO9733633 A1 WO 9733633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue adhesive
- solution
- fibrinogen
- concentration
- thrombin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00491—Surgical glue applicators
- A61B2017/00495—Surgical glue applicators for two-component glue
Definitions
- the present invention relates to a tissue adhesive applied as a two-component preparation, and more particularly to a tissue adhesive suitable for a method capable of applying a higher concentration evenly. More specifically, the present invention provides a method for spray-coating a thrombin solution with a protein solution containing fibrinogen as its essential component, by reducing the volume ratio of the thrombin solution to the high-strength fibrinogen solution. The present invention relates to a tissue adhesive suitable for obtaining a high-closing effect by uniformly forming a high-quality fiber. Background art
- Fibrinogen is a coagulation factor that plays a very important role in the final stage of the so-called blood clotting cascade. Fibrinogen is converted by thrombin from its soluble form to insoluble fibrin, which makes a significant contribution to hemostasis and wound healing, for example, in the activation of the blood coagulation system after injury.
- tissue adhesives utilizing the principle of the final phase of blood coagulation have been developed and used in surgical operations as adhesives for suture replacement of soft organs such as liver or spleen or as suture aids. At the same time, it is applied in a wide range of clinical settings.
- the ⁇ layer method '' in which the fibrinogen solution and the thrombin solution are alternately coated and applied, and the ⁇ mixing method '' in which the fibrinogen solution and the thrombin solution are simultaneously applied and mixed together.
- the multilayer method has a problem that most of the fibrinogen solution flows down before forming a fibrin gel, and the mixed method has a problem that the fibrin gel formed is non-uniform. For this reason, in the above-mentioned overlay method and mixing method, the effect of the tissue adhesive was limited.
- the clot strength and adhesive force of the fibrin gel formed by the overlay method depend on the final concentration of fibrinogen after mixing the two components. Although it rises, it remains at a constant value at about 4% or more in Oo (Basic and Clinical, ⁇ : 2399-2405 (1986); Basic and Clinical, 23: 3735-3743 (1989)).
- the fibrin gels formed in these tests are non-uniform due to the use of the overlay method and the lacquer application method, and do not fully take advantage of increasing the final concentration of fibrinogen. I can not say.
- the test is based on the so-called ⁇ mixing method '', which is a coating method based on the so-called ⁇ mixing method '', and forms a fibrin gel at a low concentration of 1-2 units / ml of thrombin after mixing the two components It is carried out under the conditions. Therefore, there is a large difference from the thrombin concentration actually used in clinical practice (250 to 500 units / ml). In particular, it is a well-known fact that coagulation time is prolonged with low-concentration tombin, and a sufficient effect cannot be obtained in tissue closing treatment which is also expected to have a hemostatic effect.
- the invention disclosed in the above-mentioned publication discloses a fibrinogen solution prepared from a lyophilized preparation previously loaded in a syringe, which can shorten the dissolving time without reducing the ultimate tensile strength of the adhesive.
- a fibrinogen solution prepared from a lyophilized preparation previously loaded in a syringe, which can shorten the dissolving time without reducing the ultimate tensile strength of the adhesive.
- the mixing ratio is changed so as to obtain the ultimate tensile strength equivalent to (10%). Therefore, the applied concentration is not practical, and does not provide a tissue adhesive means suitable for a practical application method for obtaining a high effect focusing on the closing effect as the effect of the tissue adhesive.
- an object of the present invention is to provide a tissue adhesive for spray application which can be applied as a two-component preparation and can be uniformly applied at a high concentration.
- Another object of the present invention is to provide a tissue adhesive capable of uniformly forming a high concentration of fibrin and providing a high closing effect.
- the present inventors have conducted intensive studies to achieve the above object, and found that the best method for applying a tissue adhesive is spray application, which can uniformly mix a fibrinogen solution and a thrombin solution.
- spray application which can uniformly mix a fibrinogen solution and a thrombin solution.
- To increase potency by raising the final concentration of fibrinogen after mixing the two components in a basic position, increase the sprayable fibrinogen concentration as much as possible while simultaneously mixing the fibrinogen solution and the thrombin solution.
- changing the ratio is an effective means.
- the structure of an application device for performing this method was clarified, and the present invention which can provide a tissue adhesive suitable for a method with high efficacy was completed. Disclosure of the invention
- the present invention relates to a tissue adhesive comprising a fibrinogen solution and a thrombin solution, which are mixed and spray-coated using a sterile gas for bonding or closing a living tissue of a human or an animal, and which is separated from the fibrinogen solution.
- the present invention relates to a tissue adhesive characterized by having a volume ratio with a thrombin solution of about 2 : 1 to 10: 1.
- Figure 1 is a diagram showing a method for evaluating the closure effect.
- Figure 2 is a diagram comparing the change in the closing effect when the mixing ratio is changed between the spray coating and the multilayer method.
- FIG. 3 is a plan view of a preferred instrument for applying the tissue adhesive of the present invention.
- the present invention changes the mixing ratio of the fibrinogen solution to the thrombin solution 1: 1 (volume ratio), which has been conventionally performed, reduces the volume ratio of the thrombin solution to the fibrinogen solution, and spray-coats both solutions.
- the aim is to form a high concentration of fibrin uniformly and obtain a high closing effect.
- the preferred concentrations of the fibrinogen solution and the thrombin solution are respectively 4 to 15% (w / v, 40 to 15 Omg / ml), preferably 7 to 12% (w / v).
- the mixing ratio is preferably about 2: 1 to 10: 1 (volume ratio), and particularly preferably 2: 1 to 5: 1 (volume ratio).
- the syringe body containing the fibrinogen solution and the syringe body containing the thrombin solution have the same effective stroke, and the cross-sectional area of the syringe body containing the fibrinogen solution is the same as that of the syringe body containing the thrombin solution. It is about 2 to 10 times the cross-sectional area.
- the present invention provides a further preferred embodiment of a tissue adhesive suitable for spray application.
- a tissue adhesive suitable for spray application.
- the viscosity reducing agent is not particularly limited, arginine or guanidine, which is a substance having a guanidino group, can be used. In particular, arginine and the like can be suitably used. These viscosity reducing agents can be added alone or in combination. The addition amount is preferably from 0.1 to 1.0 M, particularly preferably from 0.1 to 0.5 M.
- tissue adhesive which provides a high closing effect by uniformly forming fibrin having a degree of ⁇ .
- the test was performed using a commercially available two-component biological tissue adhesive “Bolheel” (manufactured by Chemo-Serotherapy Laboratories).
- the formulation has a fibrinogen concentration of 8% and a thrombin concentration of 250 units / ml.
- the evaluation of the closing effect was performed using the apparatus shown in FIG. That is, five 1.2-diameter holes were drilled in the cap of a plastic test tube with a needle, and a manometer and a syringe for pressurization were connected to the test tube. A tissue adhesive is applied on the cap with this hole by changing the mixing ratio by spraying or layering method, and 10 minutes after the adhesive is formed, the pressure is applied with a syringe and the pressure at which air leak starts from fiplin gel. (Burst pressure: mmHg) was recorded. The mixing ratio of the fibrinogen solution and the thrombin solution was 1: 1 or 5: 1, and 0.85 ml of the fibrinogen solution was used in each case. As shown in Fig.
- Bolheel a commercially available two-component biotissue adhesive (Chemical and Serological Research Laboratories) (Manufactured by RISO).
- the formulation has a fibrinogen concentration of 8% and a thrombin concentration of 250 units / ml.
- the closure effect was evaluated using the ability to prevent air leak in the rat lung as an index. That is, a tracheal tube was inserted into the trachea of a rat, ligated and fixed, and a force transducer, a three-way stopcock, a manometer, and a syringe for pressurization were connected to the end of the tracheal tube. After confirming that there was no air-leak, the pressure was adjusted with a syringe so that the value of the manometer indicated 15 mmHg.
- a hole with a diameter of 1.2 mm was made in the lung with a needle, and a tissue adhesive was spray-applied to the air leak at the respective mixing ratios, and a saline solution was applied to the lung 10 minutes after the adhesive was formed. Then, the air leak force from the lungs by pressurizing with a syringe, and the pressure at the start (burst pressure: mmHg) were recorded.
- the mixing ratio of the fibrinogen solution and the thrombin solution was 1: 1 or 5: 1, and 0.15 ml of the fibrinogen solution was used in each case.
- Fibrinogen prepared by the combination of cold ethanol precipitation with the effect of lowering the solubility of fibrinogen by glycine, or fibrinogen prepared by glycine precipitation using glycine alone, as a coagulable protein concentration of 7.5-11.1% (w / v) solution.
- mPa * s absolute viscosities
- FIG. 3 is a plan view of a suitable tissue adhesive application device when the tissue adhesive of the present invention is applied.
- the spraying device for tissue adhesive includes a syringe (1) containing a fibrinogen solution, a syringe (2) containing a thrombin solution, and a syringe holding means (3, 3) for fixing each syringe with its barrel (5, 6). ), Integrated operating means (4) provided at the end of each syringe plunger (7, 8) to operate each plunger (7, 8) integrally, to the spray provided at the tip of each syringe. (9) Force, etc. are composed.
- the syringe (1) has an area larger than the cross-sectional area of the syringe (2).
- the cross-sectional area ratio is 5: 1 and therefore the volume ratio is 5: 1. Effective outlet for two syringes (1, 2)
- the aseptic gas is introduced into the spray head (9) through the aseptic gas supply channel (13), and is injected from the aseptic gas injection port (14).
- the two solutions correspond to the cross-sectional area of the syringe.
- the mixture is extruded in the form of a mist through the passages and liquid pipes (11, 12) provided in the spray head (9), and sprayed as an adhesive.
- the syringe body (2) is generally formed of a material such as glass or transparent synthetic resin, for example, polypropylene or polycarbonate, and has a barrel (5, 5) having a constricted portion for connection with the spray head (9). 6) and a plunger (7, 8) that can be slidably inserted into the barrel (5, 6).
- the spray head (9) receives the sterile gas that has passed through the air filter from the sterile gas supply path (13), and injects the gas through the sterile gas injection port (14).
- liquid tubes (11, 12) for supplying a fibrinogen solution and a thrombin solution are arranged from the syringe body connection port (10) to the sterile gas injection port (14).
- the material of the spray head (9) is not particularly limited, but is usually formed of a resin such as a soft vinyl chloride resin—polyethylene, polyester, polypropylene, or a metal having high workability.
- (11, 12) is made of Teflon, vinyl chloride resin, metals, etc.
- the syringe holding means (3) holds and fixes the syringe body (1) and the syringe body (2) integrally, and may be of various shapes, but the one shown in FIG. This is an example. It has two parallel grooves on one side corresponding to the shape of the outer wall of each barrel (5, 6), the depth of which is the cross-section of the barrel (5, 6). Is larger than the radius of the groove, so that the entrance of the groove is narrow, so that when the barrel (5, 6) is installed in the groove, the barrel (5, 6) is held by the groove wall.
- the integral actuating means (4) secures the pressing parts of the two plungers (7, 8) so that the plungers (7, 8) can move together in the barrel (5, 6).
- Figure 3 shows an example. Yes, two parallel grooves for mounting the pressing parts of the plungers (7, 8) and a holding plate perpendicular to these grooves are formed in a body.
- the shape of the groove is substantially the same as the shape of the groove of the syringe holding means (3) so that the pressing portion is mounted and held in the groove.
- a gap is formed between the groove and the holding plate corresponding to the pressed portion of the plunger (7, 8).
- a synthetic resin is generally used as a material for forming the syringe holding means (3) and the integral operating means (4).
- a synthetic resin is generally used.
- polyethylene, polypropylene, acrylonitrile butadiene styrene copolymer, polycarbonate and the like can be suitably used.
- a syringe (1) filled with a fibrinogen solution and a syringe (2) filled with a thrombin solution are fixed to a syringe holding means (3).
- the fibrinogen solution and the thrombin solution are contained in the syringe (1, 2) at a volume ratio according to the cross-sectional area of the syringe.
- the spray head (9) is attached to a pair of syringe bodies (1, 2). Adjust the pressure of the sterile gas to be released, and release the sterile gas.
- the fibrinogen solution and the thrombin solution can be simultaneously atomized by the action of aseptic gas by gently pressing the integrated operating means (4) with the thumb.
- tissue adhesive of the present invention is useful in cases where a strong adhesive or closing effect is required such as adhesion or closure of human or animal living tissue, for example, treatment of large blood vessels or treatment of air leak in the lung.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97907319A EP0835667B1 (en) | 1996-03-15 | 1997-03-14 | Spray device for applying tissue adhesive |
CA002220927A CA2220927C (en) | 1996-03-15 | 1997-03-14 | Tissue adhesive suitable for spray application |
AU19411/97A AU715822B2 (en) | 1996-03-15 | 1997-03-14 | Tissue adhesive suitable for spray application |
DE69734557T DE69734557T2 (de) | 1996-03-15 | 1997-03-14 | Sprühvorrichtung zum aufbringen von gewebeklebstoff |
US08/945,882 US5980866A (en) | 1996-03-15 | 1997-03-14 | Tissue adhesive suitable for spray application |
AT97907319T ATE309006T1 (de) | 1996-03-15 | 1997-03-14 | Sprühvorrichtung zum aufbringen von gewebeklebstoff |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/87566 | 1996-03-15 | ||
JP8756696 | 1996-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997033633A1 true WO1997033633A1 (fr) | 1997-09-18 |
Family
ID=13918548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/000818 WO1997033633A1 (fr) | 1996-03-15 | 1997-03-14 | Adhesif pour tissus, applique par pulverisation |
Country Status (9)
Country | Link |
---|---|
US (2) | US5980866A (ja) |
EP (1) | EP0835667B1 (ja) |
KR (1) | KR100450142B1 (ja) |
AT (1) | ATE309006T1 (ja) |
AU (1) | AU715822B2 (ja) |
CA (1) | CA2220927C (ja) |
DE (1) | DE69734557T2 (ja) |
DK (1) | DK0835667T3 (ja) |
WO (1) | WO1997033633A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001342146A (ja) * | 2000-03-28 | 2001-12-11 | Chemo Sero Therapeut Res Inst | 液状フィブリノゲン製剤 |
US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
US7018357B2 (en) | 2001-02-27 | 2006-03-28 | Tyco Healthcare Group Lp | External mixer assembly |
WO2013172472A1 (ja) | 2012-05-14 | 2013-11-21 | 帝人株式会社 | シート成形体および止血材 |
JP2015509084A (ja) * | 2011-12-29 | 2015-03-26 | オムリックス・バイオファーマシューティカルズ・リミテッドOmrix Biopharmaceuticals Ltd. | 固体タンパク質組成物を迅速に溶解させるための方法及び装置 |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6783514B2 (en) | 1997-01-31 | 2004-08-31 | United States Surgical Corporation | Fibrin sealant applicator |
US6471670B1 (en) | 1998-10-05 | 2002-10-29 | Karl Enrenfels | Fibrin sealant applicator system |
US7654998B1 (en) | 1999-08-23 | 2010-02-02 | Aeris Therapeutics, Inc. | Tissue volume reduction |
US6509514B1 (en) * | 2000-03-17 | 2003-01-21 | Kmt Hepatech, Inc. | Chimeric animal model susceptible to human hepatitis C virus infection |
US6921532B1 (en) | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
EP1301245A4 (en) * | 2000-07-17 | 2007-02-28 | Haemacure Corp | SPRAY HEAD FOR APPLYING A MIXTURE WITH MULTIPLE COMPONENTS |
US20020147462A1 (en) * | 2000-09-11 | 2002-10-10 | Closure Medical Corporation | Bronchial occlusion method and apparatus |
US20020165483A1 (en) * | 2000-11-10 | 2002-11-07 | Curtis Miller | Gas assisted spray applicator |
US6732887B2 (en) * | 2002-03-26 | 2004-05-11 | Ultradent Products, Inc. | Two-part composition syringe delivery system |
US7077339B2 (en) * | 2003-02-03 | 2006-07-18 | Biomet, Inc. | Spray applicator |
US8206448B2 (en) * | 2004-10-29 | 2012-06-26 | Spinal Restoration, Inc. | Injection of fibrin sealant using reconstituted components in spinal applications |
US8403923B2 (en) * | 2004-10-29 | 2013-03-26 | Spinal Restoration, Inc. | Injection of fibrin sealant in the absence of corticosteroids in spinal applications |
US8419722B2 (en) * | 2004-10-29 | 2013-04-16 | Spinal Restoration, Inc. | Apparatus and method for injection of fibrin sealant in spinal applications |
US8124075B2 (en) * | 2004-07-16 | 2012-02-28 | Spinal Restoration, Inc. | Enhanced biological autologous tissue adhesive composition and methods of preparation and use |
US7597687B2 (en) * | 2004-10-29 | 2009-10-06 | Spinal Restoration, Inc. | Injection of fibrin sealant including an anesthetic in spinal applications |
EP1784640A4 (en) * | 2004-08-20 | 2010-10-06 | Kmt Hepatech Inc | ANIMAL MODEL OF MALARIA PRESENTING A CHIMERIC HUMAN LIVER |
US7766900B2 (en) | 2005-02-21 | 2010-08-03 | Biomet Manufacturing Corp. | Method and apparatus for application of a fluid |
US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US8741326B2 (en) | 2006-11-17 | 2014-06-03 | Abbott Cardiovascular Systems Inc. | Modified two-component gelation systems, methods of use and methods of manufacture |
US8192760B2 (en) | 2006-12-04 | 2012-06-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating tissue using silk proteins |
WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
US8518272B2 (en) | 2008-04-04 | 2013-08-27 | Biomet Biologics, Llc | Sterile blood separating system |
US8182769B2 (en) | 2008-04-04 | 2012-05-22 | Biomet Biologics, Llc | Clean transportation system |
CN102066943A (zh) * | 2008-04-09 | 2011-05-18 | B.R.A.H.M.S有限公司 | 用于预测受损峰值耗氧量的内皮素1原 |
US9211554B2 (en) | 2010-06-30 | 2015-12-15 | Actamax Surgical Materials, Llc | Self-contained hand-held direct drive device for dispensing a two-part adhesive aerosol |
US8678238B2 (en) | 2010-06-30 | 2014-03-25 | Actamax Surgical Materials, Llc | Self-contained hand-held yoke-connected device for dispensing a two-part adhesive aerosol |
US20130202675A1 (en) | 2012-02-03 | 2013-08-08 | Dynasil Biomedical Corporation | Systems and methods for the fabrication of tissue patches |
CN104883984A (zh) | 2012-11-05 | 2015-09-02 | 史密夫和内修公司 | 用于流体输送的组件和方法 |
USD772804S1 (en) * | 2013-09-05 | 2016-11-29 | Sony Corporation | Rechargeable battery |
WO2015153828A1 (en) | 2014-04-04 | 2015-10-08 | Hyperbranch Medical Technology, Inc. | Extended tip spray applicator for two-component surgical selant, and methods of use thereof |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
AU2016307447A1 (en) | 2015-08-07 | 2018-02-22 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55110556A (en) * | 1979-02-15 | 1980-08-26 | Immuno Ag | Tissue adhesive and its preparation |
JPS5838216A (ja) * | 1981-06-25 | 1983-03-05 | セラフアルム ジーエムビーエイチ アンド カンパニー ケイジイ | 濃縮血漿誘導体製剤 |
JPH02114A (ja) * | 1987-07-30 | 1990-01-05 | Centre Reg Transfusion Sanguine De Lille | トロンビン凝固性蛋白質の濃縮物、その製造方法及びその治療的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE20824T1 (de) * | 1981-06-25 | 1986-08-15 | Serapharm Gmbh & Co Kg | Angereichertes plasmaderivat zur unterstuetzung von wundverschluss und wundheilung. |
DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
AT382783B (de) * | 1985-06-20 | 1987-04-10 | Immuno Ag | Vorrichtung zur applikation eines gewebeklebstoffes |
JPS63174924A (ja) * | 1987-01-14 | 1988-07-19 | Toko Yakuhin Kogyo Kk | 軟膏基剤および軟膏剤 |
US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5318524A (en) * | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5030215A (en) * | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
SE9101853D0 (sv) * | 1991-06-17 | 1991-06-17 | Jonas Wadstroem | Improved tissue ashesive |
AU675051B2 (en) * | 1991-09-05 | 1997-01-23 | Baxter International Inc. | Topical fibrinogen complex |
ATE177613T1 (de) * | 1992-09-26 | 1999-04-15 | Chemo Sero Therapeut Res Inst | Applikator für gewebeklebstoff |
US5660873A (en) * | 1994-09-09 | 1997-08-26 | Bioseal, Limited Liability Corporaton | Coating intraluminal stents |
-
1997
- 1997-03-14 US US08/945,882 patent/US5980866A/en not_active Expired - Lifetime
- 1997-03-14 DK DK97907319T patent/DK0835667T3/da active
- 1997-03-14 WO PCT/JP1997/000818 patent/WO1997033633A1/ja active IP Right Grant
- 1997-03-14 AU AU19411/97A patent/AU715822B2/en not_active Ceased
- 1997-03-14 EP EP97907319A patent/EP0835667B1/en not_active Revoked
- 1997-03-14 DE DE69734557T patent/DE69734557T2/de not_active Expired - Fee Related
- 1997-03-14 AT AT97907319T patent/ATE309006T1/de not_active IP Right Cessation
- 1997-03-14 KR KR1019970708159A patent/KR100450142B1/ko active IP Right Grant
- 1997-03-14 CA CA002220927A patent/CA2220927C/en not_active Expired - Fee Related
-
1999
- 1999-04-28 US US09/299,916 patent/US6251370B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55110556A (en) * | 1979-02-15 | 1980-08-26 | Immuno Ag | Tissue adhesive and its preparation |
JPS5838216A (ja) * | 1981-06-25 | 1983-03-05 | セラフアルム ジーエムビーエイチ アンド カンパニー ケイジイ | 濃縮血漿誘導体製剤 |
JPS5838217A (ja) * | 1981-06-25 | 1983-03-05 | セラフアルム ジ−エムビ−エイチ アンド カンパニ−ケイジイ | 濃縮血漿誘導体含有製剤 |
JPH02114A (ja) * | 1987-07-30 | 1990-01-05 | Centre Reg Transfusion Sanguine De Lille | トロンビン凝固性蛋白質の濃縮物、その製造方法及びその治療的用途 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
US6682520B2 (en) | 1999-08-23 | 2004-01-27 | Bistech, Inc. | Tissue volume reduction |
US7300428B2 (en) | 1999-08-23 | 2007-11-27 | Aeris Therapeutics, Inc. | Tissue volume reduction |
US7654999B2 (en) | 1999-08-23 | 2010-02-02 | Aeris Therapeutics, Inc. | Tissue volume reduction |
JP4733283B2 (ja) * | 2000-03-28 | 2011-07-27 | 一般財団法人化学及血清療法研究所 | 液状フィブリノゲン製剤 |
JP2001342146A (ja) * | 2000-03-28 | 2001-12-11 | Chemo Sero Therapeut Res Inst | 液状フィブリノゲン製剤 |
US7018357B2 (en) | 2001-02-27 | 2006-03-28 | Tyco Healthcare Group Lp | External mixer assembly |
US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
US9775930B2 (en) | 2006-11-17 | 2017-10-03 | Abbott Cardiovascular Systems Inc. | Composition for modifying myocardial infarction expansion |
JP2015509084A (ja) * | 2011-12-29 | 2015-03-26 | オムリックス・バイオファーマシューティカルズ・リミテッドOmrix Biopharmaceuticals Ltd. | 固体タンパク質組成物を迅速に溶解させるための方法及び装置 |
US10618950B2 (en) | 2011-12-29 | 2020-04-14 | Omrix Biopharmaceuticals Ltd. | Method and device for fast dissolution of solid protein composition |
US11634473B2 (en) | 2011-12-29 | 2023-04-25 | Omrix Biopharmaceuticals Ltd. | Method and device for fast dissolution of solid protein composition |
WO2013172472A1 (ja) | 2012-05-14 | 2013-11-21 | 帝人株式会社 | シート成形体および止血材 |
Also Published As
Publication number | Publication date |
---|---|
EP0835667A1 (en) | 1998-04-15 |
KR100450142B1 (ko) | 2004-11-16 |
US5980866A (en) | 1999-11-09 |
CA2220927C (en) | 2008-04-22 |
KR19990014815A (ko) | 1999-02-25 |
US6251370B1 (en) | 2001-06-26 |
AU1941197A (en) | 1997-10-01 |
EP0835667B1 (en) | 2005-11-09 |
CA2220927A1 (en) | 1997-09-18 |
DK0835667T3 (da) | 2005-12-05 |
AU715822B2 (en) | 2000-02-10 |
ATE309006T1 (de) | 2005-11-15 |
DE69734557D1 (de) | 2005-12-15 |
EP0835667A4 (en) | 2002-02-20 |
DE69734557T2 (de) | 2006-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997033633A1 (fr) | Adhesif pour tissus, applique par pulverisation | |
US6132396A (en) | Apparatus for applying tissue sealant | |
US6461325B1 (en) | Fibrin delivery device and method for forming fibrin on a surface | |
US7018357B2 (en) | External mixer assembly | |
US5605541A (en) | Fibrin sealant applicatoor | |
JP5295168B2 (ja) | フィブリン接着剤塗布用装置 | |
JPH11506649A (ja) | 傷シーラント調製物並びに適用デバイス及び方法 | |
JPH0371894B2 (ja) | ||
JP2003534836A (ja) | 可撓性連結末端部分を有する粘着性組織シーラント用ディスペンサ | |
AU2004246860A1 (en) | Dual-ended applicator for dispensing two fluids, in particular glue components | |
Wolf Jr et al. | Comparison of fibrin glue, laser weld, and mechanical suturing device for the laparoscopic closure of ureterotomy in a porcine model | |
Kaetsu et al. | Increased effectiveness of fibrin sealant with a higher fibrin concentration | |
Minato et al. | New application method of fibrin glue for more effective hemostasis in cardiovascular surgery: rub-and-spray method | |
JPH0652839U (ja) | 生体組織接着剤用簡易塗布器具 | |
US20220296227A1 (en) | Biological tissue adhesive nebulizer and clogging prevention container | |
US20240033399A1 (en) | Methods and Devices for Changing the Flow Rates of PH Modifying Fluids for Controlling Cross-Linking Rates of Reactive Components of Biocompatible Sealing Compositions | |
CN205620240U (zh) | 一种外科手术用封合剂胀破强度检测装置 | |
US20220265938A1 (en) | Systems, devices and methods for dispensing biocompatible reactive formulations and controlling cross-linking of the reactive components of the biocompatible reactive formulations | |
JP2022146896A (ja) | 生体組織接着剤用噴霧器及び目詰まり防止容器 | |
JPH06181979A (ja) | 生体組織接着剤塗布用チューブ | |
JPH09154848A (ja) | スプレーヘッド | |
JP2003235977A (ja) | 生体組織接着剤塗布用具 | |
JP2000515770A (ja) | フィブリンシーラント用アプリケーター | |
Dorian | Method and apparatus for applying tissue sealant | |
Sierra | Failure mechanisms of fibrin-based surgical tissue adhesives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref document number: 2220927 Country of ref document: CA Kind code of ref document: A Ref document number: 2220927 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997907319 Country of ref document: EP Ref document number: 08945882 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970708159 Country of ref document: KR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1997907319 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970708159 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019970708159 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997907319 Country of ref document: EP |